Press release
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey concerning NF1-PN, a rare disease.
The report forecasts that the NF1-PN market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow from approximately USD 380 million in 2023 at a considerable CAGR by 2034. This anticipated growth is attributed to ongoing research into the genetic underpinnings of these tumors, the availability of medical therapy as an alternative to surgery, improvements in administration ease, and a decrease in side effect profiles of emerging therapies.
According to the report, the United States consistently holds the highest market share among the 7MM, with around USD 230 million in 2023.
The report provides a detailed epidemiological analysis and forecasts up to 2034, segmented by total NF1 diagnosed prevalent cases, diagnosed cases of NF1 manifestations, age-specific NF1-PN diagnosed cases, NF1-PN cases by clinical symptoms, and NF1-PN cases eligible for surgery in the 7MM. In 2023, the majority of diagnosed NF1-PN patients were estimated to be in the US, followed by Germany.
Current NF1-PN treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs from 2020 to 2034 are also addressed in the report. While surgery remains a standard treatment for many patients, it is often complex, not always feasible, carries inherent risks, and has a high possibility of tumor recurrence. A multidisciplinary approach involving genetics, neurology, radiology, and surgery, is vital for effectively managing the disease's physical and emotional impacts.
With an improved understanding of the genetic basis of plexiform neurofibromas, targeted therapies like the MEK inhibitor KOSELUGO (AstraZeneca and Merck) have emerged as promising options, especially for pediatric patients with inoperable NF1-PN. Building on this progress, researchers are exploring other MEK inhibitors for potential use in both pediatric and adult patients.
The current NF1-PN developmental pipeline includes additional MEK inhibitors such as Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Another emerging drug, HLX-1502 (Healx), offers a unique investigational treatment option for NF1 patients. In October 2024, the US FDA granted Fast Track Designation (FTD) to HLX-1502 for the treatment of NF1.
Recent developments include findings for PAS-004, which demonstrated no dose-limiting toxicities in Phase 1 clinical trials. An external Safety Review Committee recommended proceeding with its higher doses without modification in February 2025, highlighting the potential of these emerging therapies to revolutionize NF1-PN treatment.
Although NF1-PN presents significant challenges due to its highly individualized treatment needs-including multidisciplinary teamwork, tumor regrowth, and complications arising from tumors developing in critical areas like the head, neck, chest, or spine-the emergence of novel therapies as an alternative to surgery, improving administration ease and minimize side effects, is expected to broaden treatment options and enhance market growth.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF NF1-PN
4. NF1-PN EPIDEMIOLOGY AND MARKET METHODOLOGY
5. NF1-PN MARKET OVERVIEW AT A GLANCE
6. KEY EVENTS
7. NF1-PN BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND NF1-PN PATIENT POPULATION
9. NF1-PN PATIENT JOURNEY
10. NF1-PN MARKETED DRUGS
11. NF1-PN EMERGING DRUGS
12. NF1-PN: SEVEN MAJOR MARKET ANALYSIS
13. NF1-PN UNMET NEEDS
14. NF1-PN MARKET SWOT ANALYSIS
15. KOL VIEWS
16. MARKET ACCESS AND REIMBURSEMENT
17. APPENDIX
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Related Reports
Plexiform Neurofibroma Market Insight [https://www.delveinsight.com/report-store/plexiform-neurofibroma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Plexiform Neurofibroma Market Insight, Epidemiology And Market Forecast report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Plexiform Neurofibroma market trends, market drivers, market barriers, and key Plexiform Neurofibroma companies, including SpringWorks Therapeutics, Array BioPharma, Novartis, Shanghai Fosun Pharmaceutical Development Co, Ltd.,and Ashvattha Therapeutics, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-nf1pn-market-size-in-7mm-to-witness-notable-growth-expanding-from-usd-380-million-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight here
News-ID: 4128581 • Views: …
More Releases from ABNewswire
BiG Agency Announces Leadership Change, Reinforces Commitment to Innovation, Tra …
As the company enters a key growth phase, CEO Hani Rihan reaffirms BiG's mission to protect families, empower agents, and lead the insurance industry forward.
Tampa, FL - BiG Agency [http://www.bestinsurancegroup.net] today announced a significant leadership change as part of its ongoing evolution and focus on sustained growth and performance. Effective immediately, Travis Yoder is no longer with BiG Agency.
"We want to thank Travis for his time and contributions to BiG,"…
NEXCOM Showcases Safe Humanoid Robot Controller, and unveils Slim AI-Ready Panel …
Image: https://www.abnewswire.com/upload/2025/10/c16b34d2259e32d30c2f0e68467204ea.jpg
New Taipei City, Taiwan - October 21st, 2025 - NEXCOM will present the newest advancements in software-defined (SD) edge and AI computing, and AIoT solutions at Embedded World North America 2025. NEXCOM's booths will feature the SPPC 16-10N150 Slim Touchscreen Computer, the ATC 3561-NA4C Rugged Edge AI Computer for Smart Agriculture, and other innovative NEXCOM products, including the MARS400 T10 Safety-Centric Humanoid Robot Controller.
SPPC 16-10N150 Slim Touchscreen Computer
NEXCOM's SPPC…
McKayLawTx.com Brings Community Spirit to Winnsboro Chili Cook-Off Festival
More Than Just a Law Firm: Building Community Connections "We believe in being part of the fabric of the communities we serve, not just serving them when legal needs arise," said Lindsey McKay of McKay Law. "Events like the Winnsboro Chili Cook-Off represent what makes Texas special-neighbors coming together, supporting local traditions, and building relationships that matter. We were honored to participate and meet so many wonderful people."
WINNSBORO, TX -…
Frontotemporal Dementia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinica …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Frontotemporal Dementia pipeline constitutes 15+ key companies continuously working towards developing 20+ Frontotemporal Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Frontotemporal Dementia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.
The Frontotemporal Dementia Pipeline report…
More Releases for NF1
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market?
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new…
